Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference
January 04 2022 - 7:30AM
Business Wire
Company to Review Milestones for its Phase 2b
Study of FX-322, the Near-Term Clinical Plan for its Second Hearing
Restoration Asset, FX-345, and Selection of a Lead Candidate for
its Novel Multiple Sclerosis Program that Has Shown Potent
Pre-Clinical Data
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a
clinical-stage regenerative medicine company focused on developing
therapeutics to activate a person’s innate regenerative potential
to restore function, today announced that Chief Executive Officer
David L. Lucchino will present a Company overview at the 40th
Annual J.P. Morgan Healthcare Conference.
Mr. Lucchino’s presentation will take place on January 13th at
10:30 a.m. ET and will be followed by a question-and-answer session
immediately thereafter. A live webcast of both the presentation and
the breakout session can be accessed on the investors section of
Frequency’s website, investors.frequencytx.com. A replay of the
presentation will be posted on the Frequency website following the
event.
About Frequency Therapeutics
Frequency Therapeutics is leading a new category in regenerative
medicine that aims to restore function – first in hearing loss and
then in multiple sclerosis (MS) – by developing therapeutics that
activate a person’s innate regenerative potential within the body
through the activation of progenitor cells to restore lost
function. Frequency’s hearing research focuses on cochlear
restoration and auditory repair, and its lead asset, FX-322, is a
small-molecule product candidate that is the first to show
statistically significant and clinically meaningful hearing
improvements in clinical trials for SNHL. Frequency is also
following early restorative signals in MS to develop medicines with
the same underlying regenerative science being brought to hearing
loss.
Headquartered in Lexington, Mass., Frequency has an ex-U.S.
license and collaboration agreement with Astellas Pharma Inc. for
FX-322, as well as additional collaboration and licensing
agreements with academic and nonprofit research organizations
including Massachusetts Eye and Ear, Mass General Brigham, the
Massachusetts Institute of Technology, the Scripps Research
Institute and Cambridge Enterprises Limited. For more information,
visit www.frequencytx.com and follow Frequency on Twitter
@Frequencytx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220104005237/en/
Investors: Carlo Tanzi, Ph.D. Kendall Investor Relations
ctanzi@kendallir.com 617-914-0008
Media: Suzanne Day Frequency Therapeutics
sday@frequencytx.com 781-496-2211
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From Sep 2023 to Sep 2024